For the past 18 months, Irish medtech start-up Deciphex has been working to open its own pathological testing lab in the UK. Deciphex has already proven to be very popular in the UK by providing access to additional pathologists to an overstretched NHS. On Tuesday, the company secured a critical approval from the UK Accreditation Service (Ukas) to push further into the market by conducting its own pathological tests – as opposed to just reviewing them. “I think it’s transformative on multiple levels,” Deciphex CEO Donal O’Shea told The Currency, as the company announced the opening of a new test…

Read on for just €1

For a limited time, get your first month for €1 and unlock full access to The Currency and The Wall Street Journal – two premium memberships, one subscription.

Subscribe

Cancel at any time.

Are you already a member? .